IBDEI0C5 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5765,2)
 ;;=^331808
 ;;^UTILITY(U,$J,358.3,5766,0)
 ;;=250.00^^49^517^14
 ;;^UTILITY(U,$J,358.3,5766,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5766,1,4,0)
 ;;=4^DMII w/o COMPLICATIONS
 ;;^UTILITY(U,$J,358.3,5766,1,5,0)
 ;;=5^250.00
 ;;^UTILITY(U,$J,358.3,5766,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,5767,0)
 ;;=250.10^^49^517^10
 ;;^UTILITY(U,$J,358.3,5767,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5767,1,4,0)
 ;;=4^DMII w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,5767,1,5,0)
 ;;=5^250.10
 ;;^UTILITY(U,$J,358.3,5767,2)
 ;;=^331783
 ;;^UTILITY(U,$J,358.3,5768,0)
 ;;=250.20^^49^517^9
 ;;^UTILITY(U,$J,358.3,5768,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5768,1,4,0)
 ;;=4^DMII w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,5768,1,5,0)
 ;;=5^250.20
 ;;^UTILITY(U,$J,358.3,5768,2)
 ;;=^331787
 ;;^UTILITY(U,$J,358.3,5769,0)
 ;;=250.40^^49^517^12
 ;;^UTILITY(U,$J,358.3,5769,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5769,1,4,0)
 ;;=4^DMII w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,5769,1,5,0)
 ;;=5^250.40
 ;;^UTILITY(U,$J,358.3,5769,2)
 ;;=^331795
 ;;^UTILITY(U,$J,358.3,5770,0)
 ;;=250.50^^49^517^8
 ;;^UTILITY(U,$J,358.3,5770,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5770,1,4,0)
 ;;=4^DMII w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,5770,1,5,0)
 ;;=5^250.50
 ;;^UTILITY(U,$J,358.3,5770,2)
 ;;=^331799
 ;;^UTILITY(U,$J,358.3,5771,0)
 ;;=250.60^^49^517^11
 ;;^UTILITY(U,$J,358.3,5771,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5771,1,4,0)
 ;;=4^DMII w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,5771,1,5,0)
 ;;=5^250.60
 ;;^UTILITY(U,$J,358.3,5771,2)
 ;;=^331803
 ;;^UTILITY(U,$J,358.3,5772,0)
 ;;=250.70^^49^517^13
 ;;^UTILITY(U,$J,358.3,5772,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5772,1,4,0)
 ;;=4^DMII w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,5772,1,5,0)
 ;;=5^250.70
 ;;^UTILITY(U,$J,358.3,5772,2)
 ;;=^331807
 ;;^UTILITY(U,$J,358.3,5773,0)
 ;;=272.0^^49^518^4
 ;;^UTILITY(U,$J,358.3,5773,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5773,1,4,0)
 ;;=4^PURE HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,5773,1,5,0)
 ;;=5^272.0
 ;;^UTILITY(U,$J,358.3,5773,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,5774,0)
 ;;=272.1^^49^518^5
 ;;^UTILITY(U,$J,358.3,5774,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5774,1,4,0)
 ;;=4^PURE HYPERGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,5774,1,5,0)
 ;;=5^272.1
 ;;^UTILITY(U,$J,358.3,5774,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,5775,0)
 ;;=272.2^^49^518^3
 ;;^UTILITY(U,$J,358.3,5775,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5775,1,4,0)
 ;;=4^MIXED HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,5775,1,5,0)
 ;;=5^272.2
 ;;^UTILITY(U,$J,358.3,5775,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,5776,0)
 ;;=272.4^^49^518^1
 ;;^UTILITY(U,$J,358.3,5776,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5776,1,4,0)
 ;;=4^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,5776,1,5,0)
 ;;=5^272.4
 ;;^UTILITY(U,$J,358.3,5776,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,5777,0)
 ;;=272.6^^49^518^2
 ;;^UTILITY(U,$J,358.3,5777,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5777,1,4,0)
 ;;=4^LIPODYSTROPHY
 ;;^UTILITY(U,$J,358.3,5777,1,5,0)
 ;;=5^272.6
 ;;^UTILITY(U,$J,358.3,5777,2)
 ;;=^71106
 ;;^UTILITY(U,$J,358.3,5778,0)
 ;;=253.0^^49^519^1
 ;;^UTILITY(U,$J,358.3,5778,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5778,1,4,0)
 ;;=4^ACROMEGALY AND GIGANTISM
 ;;^UTILITY(U,$J,358.3,5778,1,5,0)
 ;;=5^253.0
 ;;^UTILITY(U,$J,358.3,5778,2)
 ;;=^2351
 ;;^UTILITY(U,$J,358.3,5779,0)
 ;;=255.0^^49^519^2
 ;;^UTILITY(U,$J,358.3,5779,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5779,1,4,0)
 ;;=4^CUSHING'S SYNDROME
 ;;^UTILITY(U,$J,358.3,5779,1,5,0)
 ;;=5^255.0
